Understanding clinical significance, and the new epinephrine nasal spray
Mar 23, 2026 - 18:30
Radio and PodcastLive Radio & PodcastsIn this podcast recorded in early February, David Phizackerley and Julian Treadwell (DTB Associate Editor) provide an overview of the March 2025 issue of DTB. Julian talks about his work as an academic GP based at Bristo...
Paying the price, liver problems with fezolinetant, systemic anticancer treatments is an episode from DTB podcast by BMJ Group. In this podcast recorded in early February, David Phizackerley and Julian Treadwell (DTB Associate Editor) provi...
This episode belongs to DTB podcast.
Use the player on this page to stream the episode online.
Published Mar 3, 2025, 31:57 long, audio available.
In this podcast recorded in early February, David Phizackerley and Julian Treadwell (DTB Associate Editor) provide an overview of the March 2025 issue of DTB. Julian talks about his work as an academic GP based at Bristol University. He explains why and how he developed the GP Evidence website ( ) as a resource for health professionals to use as part of a shared decision making process, and talks about the importance of providing patients with information on the absolute benefits and harms of different treatment options for long-term conditions. The editorial discusses a paper published in The Lancet on the population-health impact of new drugs recommended by NICE and highlights the tension between NICE's role in ensuring that treatments are a cost-effective use of taxpayers’ money and its role in championing the for-profit life-sciences - . A DTB Select item summarises safety alerts issued by the US Food and Drug Administration and the European Medicines Agency on liver problems associated with fezolinetant (▼Veoza), a drug licensed for the treatment of moderate-to-severe vasomotor symptoms associated with the menopause - . The main article provides an overview of systemic anticancer treatments and conventional cytotoxic drugs - . Links GP Evidence ( ) Naci H, Murphy P, Woods B, et al. Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis. The Lancet 2025;405:50–60. ( ) Please
You can listen to Paying the price, liver problems with fezolinetant, systemic anticancer treatments online on Radio and Podcast. Open the player on this page to stream the available audio.
Paying the price, liver problems with fezolinetant, systemic anticancer treatments is an episode from DTB podcast by BMJ Group.
This episode is 31:57 long.
This episode was published on Mar 3, 2025.
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Yes. This page shows related episodes from DTB podcast when more episodes are available from the podcast feed.
You can listen to Paying the price, liver problems with fezolinetant, systemic anticancer treatments on this page when the episode audio is available from the podcast feed.
Paying the price, liver problems with fezolinetant, systemic anticancer treatments is from DTB podcast by BMJ Group.
Published Mar 3, 2025 and 31:57 long